Table 1 Descriptive analysis of the eligible participants for injectable treatment in the prebupIV survey (n = 371 participants)
Questionnaire online (n = 95) | Questionnaire face-to-face (n = 276) | P-value | Total (n = 371) | |
|---|---|---|---|---|
Gender | 0.03 | |||
male | 66 (72) | 226 (82) | 292 (80) | |
female | 26 (28) | 48 (18) | 74 (20) | |
Age – yearsa | ||||
Median [IQR] | 31 [24; 40] | 34 [29; 40] | 0.02 | 33 [28; 40] |
Stable housing | 0.61 | |||
No | 37 (39) | 116 (42) | 153 (42) | |
Yes | 57 (61) | 158 (58) | 215 (58) | |
Employment | 0.02 | |||
No | 53 (58) | 196 (72) | 249 (68) | |
Yes | 38 (42) | 77 (28) | 115 (32) | |
Opioid most injectedb | 0.17 | |||
Morphine sulfate | 14 (15) | 50 (18) | 64 (17) | |
Heroin | 21 (22) | 35 (13) | 56 (15) | |
Buprenorphinec | 52 (55) | 164 (59) | 216 (58) | |
Other prescription opiatesd | 8 (8) | 27 (10) | 35 (10) | |
Main reason for injecting | 0.27 | |||
To get “high” | 19 (20) | 53 (27) | 72 (24) | |
To avoid withdrawal or to feel good enough for daily functioning | 60 (65) | 109 (55) | 169 (58) | |
Pleasure of the act | 14 (15) | 38 (19) | 52 (18) | |
Cocaine useb | < 0.001 | |||
No | 67 (72) | 116 (42) | 183 (50) | |
Yes | 26 (28) | 157 (58) | 183 (50) | |
Benzodiazepine useb | 0.223 | |||
No | 68 (73) | 181 (66) | 249 (68) | |
Yes | 25 (27) | 92 (34) | 117 (32) | |
Alcohol consumptionb | < 0.001 | |||
No | 71 (75) | 141 (51) | 212 (57) | |
Yes | 24 (25) | 135 (49) | 159 (43) | |
Injection-related complications | 0.84 | |||
≤ 5 complications | 81 (85) | 233 (84) | 314 (85) | |
> 5 complications | 14 (15) | 43 (16) | 57 (15) | |
History of overdose | 0.89 | |||
No | 74 (78) | 213 (77) | 287 (77) | |
Yes | 21 (22) | 63 (23) | 84 (23) | |
Currently on OMT | 0.43 | |||
No | 20 (21) | 53 (19) | 73 (20) | |
Yes | 75 (79) | 223 (81) | 298 (80) | |
Self-reported HCV status | 0.020 | |||
No | 70 (79) | 170 (65) | 240 (69) | |
Yes | 19 (21) | 90 (35) | 109 (31) | |